CTOs on the Move

IsoPlexis

www.isoplexis.com

 
IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.isoplexis.com
  • 35 NorthEast Industrial Road
    Branford, CT USA 06405
  • Phone: 475.221.8402

Executives

Name Title Contact Details

Funding

IsoPlexis raised $25M on 05/14/2019
IsoPlexis raised $20M on 01/09/2020
IsoPlexis raised $50M on 01/07/2021
IsoPlexis raised $85M on 01/07/2021

Similar Companies

LA Habilitation House

LA Habilitation House is a Long Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Escient Pharmaceuticals

Based in San Diego, we are led by an experienced team of entrepreneurs with deep roots in this region`s life sciences ecosystem and specific expertise in GPCR drug discovery and development. Escient Pharmaceuticals is supported by top-tier life-sciences investors with a proven track record for identifying and supporting successful, next-generation medicines companies.

Immunomic Therapuetics

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing ground-breaking next generation LAMP DNA vaccines, beginning with allergy, cancer and infectious disease.

ECHO

Discover Echo redefines traditional microscope design. Experience our award-winning Automated, Fluorescence, and Transmitted Light Microscopes.